Canada’s Drug Agency is recommending public coverage for donanemab, a disease-modifying treatment for early-stage Alzheimer’s disease, though the expert committee set strict pricing and clinical conditions before provincial drug plans should pay the estimated $47,250 annual cost. According to a draft report released by the Canadian Drug Expert Committee, the infusion therapy provides clinical benefits by slowing cognitive and functional decline, marking a development for the estimated 771,939 people in Canada living with dementia as of January 2025.
Public Coverage Conditions for Donanemab
The expert committee supported donanemab reimbursement by an 11-to-3 vote, but attached several mandatory conditions for public drug plans. According to the committee’s findings, coverage should be strictly limited to adult patients aged 50 and older who have a clinical diagnosis of mild cognitive impairment or mild dementia caused by Alzheimer’s disease. Furthermore, patients must not be homozygous for the APOE4 gene variant, which represents the highest genetic risk factor for late-onset Alzheimer’s. The committee also stated that pricing must be significantly reduced before public reimbursement proceeds.
Pro Tip: According to the Alzheimer Society of Canada, receiving a timely diagnosis is critical because the medication is effective only for those in the earliest stages of the disease.
Comparing Canada’s Two Approved Alzheimer’s Treatments
Donanemab, marketed as Kisunla, is one of two disease-modifying treatments approved by Health Canada, alongside lecanemab, which is sold under the brand name Leqembi. While both therapies target and clear beta-amyloid proteins in the brain, they carry distinct financial costs and regulatory timelines.
- Donanemab (Kisunla): Approved by Health Canada in May following a review that began in February 2024. Carries an annual cost of $47,250 per patient, with draft public reimbursement recommendations issued on Thursday.
- Lecanemab (Leqembi): Approved by Health Canada last October. Carries an annual cost of approximately $30,000 to $32,000, with Canada’s Drug Agency reversing an earlier negative stance to recommend public coverage in July under specific monitoring conditions.
Industry Reaction and Access Timelines
Mathilde Merlet, president and general manager of Lilly Canada Inc., welcomed the draft recommendation as a historic milestone for patients diagnosed with early symptomatic Alzheimer’s disease. In an official statement, Merlet noted that timely intervention offers the greatest impact in slowing the progression of the disease. However, the Alzheimer Society of Canada cautions that it can take more than a year for the medication to become accessible through private plans and more than two years through public plans.
Frequently Asked Questions
Are donanemab and lecanemab cures for Alzheimer’s disease?
No. Neither medication is considered to be a cure. They are designed to slow cognitive decline, allowing patients to stay in the mild stages of the disease for longer.
What are the primary side effects associated with these treatments?
Both therapies can cause amyloid-related imaging abnormalities, which may present as temporary swelling or bleeding in the brain. Regulatory agencies and expert committees require regular MRIs to monitor patients for these specific risks.
Who is eligible to receive donanemab under the proposed public guidelines?
The Canadian Drug Expert Committee recommends limiting public coverage to adults aged 50 and older with mild cognitive impairment or mild dementia due to Alzheimer’s, provided they are not homozygous for the APOE4 gene variant and the price is significantly reduced.
Stay Informed on Healthcare Updates
Subscribe to our newsletter to receive weekly medical news and health policy updates delivered directly to your inbox every Sunday.
Related reading